Profile
Denis Zeyer currently works at NovAliX SAS, as Chief Executive Officer from 2009 and Urania Therapeutics SAS, as Director.
Denis Zeyer active positions
| Companies | Position | Start |
|---|---|---|
NovAliX SAS
 NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Chief Executive Officer | 2008-12-31 |
Urania Therapeutics SAS
 Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
NovAliX SAS
NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Health Technology |
Urania Therapeutics SAS
Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Health Technology |
- Stock Market
- Insiders
- Denis Zeyer
